FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine, namely to a method for simulating helicobacteriosis. For this purpose orally administered to white mice once day 52 mcg of Pariet preparation, which is a proton pump inhibitor in stomach, with subsequent introduction to animals in 1–1.5 hours orally once a day suspension of bacteria Helicobacter pylori KM-11RifR on isotonic solution of sodium chloride in amount of 0.2 ml, containing 1×105 microbial cells, wherein introduction of suspension of bacteria Helicobacter pylori KM-11RifR continue for 10 days, collecting faeces daily to determine the amount of helicobacteria removed from the animal body, by sowing the excrements on selective dense nutrient medium with rifampicin 150 mcg×ml-1 in petri dishes, which are incubated at temperature 37 °C for 24–48 hours in microaerophilic conditions, then treated results of sowing excrements, based on the number of grown colonies, and are judged on the survival and survival of bacteria Helicobacter pylori KM-11RifR in the stomach, based on the value of the percentage of viable bacteria Helicobacter pylori KM-11RifR of the number of orally administered animals, as well as on the beginning of bacterial release of Helicobacter pylori KM-11RifR with faeces of animals, intensity, duration and duration of bacterial release of Helicobacter pylori KM-11RifR on the basis of counting colonies grown in microaerophilic conditions at temperature 37 °C with daily selection and sowing of selected white mice faeces on selective dense nutrient medium with rifampicin at following quantitative ratio of components, g/l: peptone 20.0; yeast extract 5.0; sodium chloride 10.0; glucose 5.0; thiamine chloride 0.008; calcium pantothenate 0.008; sodium sulphite 0.5; hemin 0.01; agar-agar 12.0; tween-80 1.0; rifampicin 150 mcg⋅ml-1; distilled water – balance, pH of medium – 7.3 ± 0.2 units of pH.
EFFECT: invention enables to study survival rate, colonizing ability and persistence in organism of Helicobacter pylori bacteria and caused by pathological changes in stomach and in intestinal parts, as well as to evaluate effectiveness of new agents for treatment and prevention of helicobacteriosis.
3 cl, 2 dwg, 2 ex
